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Abstract: The purpose of this study was to investigate the effects of two types of Transcutaneous
Electrical Nerve Stimulation (TENS) on walking distance and measures of pain in
patients with Peripheral Arterial Disease (PAD) and Intermittent Claudication (IC). In a
phase 2a study, forty participants with PAD and IC completed a graded treadmill test
on two separate testing occasions. Active TENS was applied to the lower limb on the
first occasion and placebo TENS on the second. Participants were divided into two
experimental groups. One group received High-Frequency TENS (HF-TENS), the other
Low-Frequency TENS (LF-TENS). Measures taken were: Initial Claudication Distance
(ICD), Functional Claudication Distance (FCD) and Absolute Claudication Distance
(ACD). The McGill Pain Questionnaire (MPQ) vocabulary was completed at the end of
the intervention and the MPQ-Pain Rating Index (PRI) score calculated. Four
participants were excluded from the final analysis due to non-completion of the
experimental procedure. Median walking distance increased with HF-TENS for all
measures (p < .05, Wilcoxon signed ranks test, all measures). Only ACD increased
significantly with LF-TENS compared to placebo (Mdn = 179 to 228, Ws = 39, z =
2.025, p = 0.043, r = 0.48). No difference was observed between reported median
MPQ-PRI scores: 21.5 with placebo TENS and 21.5 with active TENS (p = .41). TENS
applied to the lower limb of patients with PAD and IC was associated with increased
walking distance on a treadmill but not with any reduction in pain. TENS may be a
useful adjunctive intervention to help increase walking performance in patients with IC.
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Abstract 
The purpose of this study was to investigate the effects of two types of Transcutaneous 
Electrical Nerve Stimulation (TENS) on walking distance and measures of pain in patients with 
Peripheral Arterial Disease (PAD) and Intermittent Claudication (IC). In a phase 2a study, forty 
participants with PAD and IC completed a graded treadmill test on two separate testing 
occasions. Active TENS was applied to the lower limb on the first occasion and placebo TENS on 
the second. Participants were divided into two experimental groups. One group received High-
Frequency TENS (HF-TENS), the other Low-Frequency TENS (LF-TENS). Measures taken were: 
Initial Claudication Distance (ICD), Functional Claudication Distance (FCD) and Absolute 
Claudication Distance (ACD). The McGill Pain Questionnaire (MPQ) vocabulary was completed 
at the end of the intervention and the MPQ-Pain Rating Index (PRI) score calculated. Four 
participants were excluded from the final analysis due to non-completion of the experimental 
procedure. Median walking distance increased with HF-TENS for all measures (p < .05, Wilcoxon 
signed ranks test, all measures). Only ACD increased significantly with LF-TENS compared to 
placebo (Mdn = 179 to 228, Ws = 39, z = 2.025, p = 0.043, r = 0.48). No difference was observed 
between reported median MPQ-PRI scores: 21.5 with placebo TENS and 21.5 with active TENS 
(p = .41). TENS applied to the lower limb of patients with PAD and IC was associated with 
increased walking distance on a treadmill but not with any reduction in pain. TENS may be a 
useful adjunctive intervention to help increase walking performance in patients with IC.  
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TEXT 
Introduction:  
Peripheral Arterial Disease (PAD) is a clinical manifestation of atherosclerosis. Intermittent 
claudication (IC) is the most common manifestation, and is reported to affect between 10 and 
30% of the population aged above 60 years of age.1 PAD can be asymptomatic in the early 
stages, however as the disease progresses, the increasing atherosclerosis manifests as IC,2 
which is the cardinal symptom of PAD. IC is defined as pain in the lower limb(s) that is 
experienced during walking, and is relieved by rest.3,4 Patients experiencing IC are characterised 
by reduced levels of daily physical activity, which is associated with diminished performance of 
personal, social and occupational activities of daily life. Many individuals become housebound 
or dependent on others5,6 and studies suggest that patients with severe IC have a quality of life 
that equates to those with terminal cancer.7  
 
The management of PAD and IC is primarily through the modification of risk factors, with 
endovascular intervention in severe cases and most medical therapies having only a modest 
benefit. 8,9 Exercise therapy, particularly supervised, is a mainstay of PAD and IC management 
that has been shown to have a significant effect on increasing walking distance, self-reported 
physical activity, measured cardio-respiratory fitness, exercise time and functional ability.3,10-16 
Despite the clear benefits of exercise therapy, over 45% of patients are non-compliant with 
healthcare professional advice to take regular exercise and to walk ‘through’ IC pain.11 The pain 
associated with IC has been identified as a key barrier to walking.17 Although acknowledged as a 
problem, there is little published literature examining analgesic interventions for IC pain.  
 
Transcutaneous Electrical Nerve Stimulation (TENS) is a safe, inexpensive and non-invasive 
method of providing mild electrical stimulation for the relief of pain.18,19 TENS has been 
reported to provide greater analgesic effects than placebo TENS for musculoskeletal,20 
postoperative21 and neuropathic pain.22 Packaged in a compact, portable unit that is easy to 
apply via small electrodes placed on the skin, a TENS unit can be kept unobtrusively in a pocket, 
or clipped to a trouser belt whilst being used to reduce pain and improve daily functioning.23 
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However, thus far TENS has not been tested as a method of reducing pain and improving 
walking related function in patients with IC pain.  
 
There are two main stimulation patterns, or dosages, of TENS employed in clinical practice: 
High-Frequency TENS (HF-TENS) and Low Frequency TENS (LF-TENS). Studies conducted to date 
suggest that the fast-acting, reflexive mechanism of HF-TENS may act most effectively at the 
mild (pain threshold) level of the pain experience. LF-TENS however may act most effectively at 
the stronger (pain tolerance) level of the pain experience due to extrasegmental but longer-
lasting analgesic effects.23  
 
In addition, although TENS has not been widely tested as a method of pain relief of IC, a 
previous investigation observed reductions in pain (hypoalgesia) with High Frequency TENS (HF-
TENS) in healthy volunteers experiencing experimentally-induced ischaemic pain in the lower 
limb.24 This may be due to the focus on exercise, and endovascular intervention as treatments 
for the condition and limited investigation into the nature of IC pain. Also the potential for high 
frequency verses low frequency patterns of TENS to affect different portions of the IC pain 
experience has not been examined.  
 
We hypothesised that the two types of TENS might favourably, but differentially, affect discrete 
portions of the IC pain experience; for instance, when pain is mild (which normally occurs in 
PAD patients after walking a short distance), or when it becomes more severe (during 
continued walking). We therefore aimed to investigate the effects of HF and LF-TENS on 
measures of pain and walking performance in patients with PAD and IC.  
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Material and Methods:  
Participants:  
Ethical approval for the study was obtained from the NHS East of Scotland Research Ethics 
Service (Reference Number: 09/S1402/15). Forty participants with stable PAD and IC were 
recruited from the vascular outpatient clinic at Ninewells Hospital, Dundee, Scotland and block 
randomised into two experimental groups (HF-TENS and LF-TENS). Participants provided 
written informed consent and were included if they had: clinical diagnosis of PAD and stable IC 
of more than 3 months duration; Fontaine stage II claudication; resting Ankle Brachial Index 
(ABI) less than 0.90 in at least one leg; walking limited only by claudication; independent and 
safe mobility (no walking aids); were cognitively stable and able to follow instruction and were 
able to read and complete the questionnaires. Participants were excluded if they were: less 
than 40 years of age; had planned surgical or endovascular intervention for PAD; co-morbidities 
causing pain in the lower limb; ataxic gait or history of increased falls (unsafe for treadmill 
walking); myocardial infarction within the previous 6 months, cardiac arrhythmia or a cardiac 
pacemaker; current or previous sensation abnormalities in the lower limbs; epilepsy; medical 
diagnosis or self-reported psychiatric illness or previous experience of using TENS.  
 
Study Protocol:  
The experimental study design was a single blind, placebo-controlled, phase 2a, proof-of-
concept trial. Each participant attended for two sessions, six to nine days apart with the 
majority of participants (n=30) completing both tests within seven days. A graded treadmill 
protocol25 was completed by the participant at each. On the first occasion active TENS was 
applied and placebo TENS (P-TENS) on the second. For the purpose of blinding, the participants 
were told that “different ‘dosages’ of TENS were being tested, some of which may not be 
perceptible”. To enhance blinding and reduce the risk of bias, one researcher applied the TENS 
and a different researcher, who was blinded to the study protocol and the order of 
intervention, conducted the treadmill test and recorded the primary outcome measures.  
 
Treadmill Procedure: 
 1 
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The treadmill procedure followed that described by Gardner et al 25 using a GE Marquette 
treadmill. Participants were connected to a 12-lead Echocardiograph (12-lead ECG) (GE CASE 
Premium Stress System), which recorded continuously throughout the procedure. A 
familiarisation session was completed first where participants practiced walking at different 
speeds (1, 1.5 and 2mph) and the self-report method of rating claudication symptoms was 
explained. Further safety instructions were also issued: the participants were reminded to 
report any feelings of pain distinct from claudication and any feelings of dizziness/light-
headedness immediately so that the test could be stopped. This series of events took less than 
10 minutes to complete and the participant walked for a maximum of 30 seconds at each 
treadmill speed. Once this familiarisation procedure was completed, participants rested supine 
on a bed for 15 minutes in preparation for the full treadmill test.  
 
TENS Procedure:  
A NeuroTrac 3™ TENS machine (Verity Medical Ltd, Surrey, UK) was fitted to the participant five 
minutes prior to each treadmill test and continued throughout the procedure. A segmental 
electrode application was employed using self-adhesive carbon rubber electrodes measuring 
5x5 cm (PhysioMed PALS® electrodes, Glossop, UK). The two electrodes were attached to the 
TENS unit via the manufacturer leads. The area of pain reported by the participant during the 
familiarisation session determined the electrode placement sites. The placement sites were at 
least 2cm apart. Electrodes were commonly placed with one proximal and one distal to the 
gastrocnemius muscle belly.  
 
The TENS machine was calibrated prior to use with a digital oscilloscope and tested manually by 
the investigator prior to every testing session. The HF-TENS stimulation parameters were 
calibrated to 120Hz, pulse width 200μs and patient determined intensity of “strong but 
comfortable”. The LF-TENS stimulation was set at 2Hz, pulse width 200μs and patient 
determined intensity of “strong but comfortable and slight muscle twitch”.  
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The placebo TENS (P-TENS) condition used the same TENS model and programmed settings but 
with an inconspicuous break in the wires. This allowed the unit to be switched on with the 
appearance of a working unit but without any current reaching the participant. This was 
checked and confirmed with the use of an oscilloscope as described above.  
 
Measures:  
Participants were instructed to report:  
1. When they first experienced claudication symptoms (Initial Claudication Distance (ICD)) 
25 
2. When they reached the point at which they would usually stop walking (Functional 
Claudication Distance (FCD)) 26,27 
3. When they could not walk any further due to claudication symptoms (Absolute 
Claudication Distance (ACD)) 25  
 
Pain quality and intensity was recorded using a McGill Pain Questionnaire (MPQ); 28 
administered 5 minutes after the participant completed the treadmill protocol. The MPQ 
consists of a vocabulary of adjectives from which the participant chooses appropriate words to 
describe the particular qualities of IC pain and accompanying feelings of distress and 
intrusion.29  
 
Statistical Analysis:  
The mean scores for ICD, FCD and ACD were positively skewed and showed heteroscedascity. A 
log (10) transformation applied to normalise the data did not address the variance within the 
data, thus non-parametric statistics were used to analyse the data.  
 
Wilcoxon Signed Ranks tests examined within-group differences in treadmill measures and 
MPQ-PRI scores. In order to reduce the effect of inter-participant variability, individual change 
in ICD, FCD and ACD between P-TENS and Active TENS was calculated for each participant. 
Distance walked with P-TENS was subtracted from the distance walked with Active TENS. 30 
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Individual percentage change was also calculated for ICD, FCD and ACD. The difference between 
the two sessions was calculated as a percentage of the distance walked with P-TENS. These 
values were then analysed using Mann-Whitney U tests for between-group comparisons. 
Statistical significance was set at p = 0.05 (two-tailed) and analysis was performed using SPSS 
version 19.0.  
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Results:  
Participants:  
Four participants were excluded from analysis due to non-completion of the experimental 
procedure. Three had previously unknown exercise-limiting co-morbidities and one was unable 
to walk safely on the treadmill. The remaining 36 participants (18 in each group) were included 
in the analysis (29 male, mean age (range) = 70 (54-87) years). Figure 1 summarises this 
information and displays the flow of participants through the study. The groups were similar in 
terms of demographic and disease data. The LF-TENS group had a significantly lower mean ABI 
(0.57 vs 0.63, t(34) = 2.442) (Table 1). 
 
Within Group Profiles (HF-TENS and LF-TENS vs. P-TENS):  
ICD, FCD and ACD results are detailed in Table 2. Compared to placebo TENS, median walking 
distance increased with TENS intervention in both groups. This was true with the exception of 
FCD in the HF-TENS group (Mdn 187 to 175m) and ICD in the LF-TENS group (Mdn 81 to 76m). 
All walking-related outcome measures changed with HF-TENS intervention. Only ACD changed 
with LF-TENS intervention (Mdn 179 to 288m, Ws = 39, z = 2.025, p = 0.043, r = 0.48). There was 
no change in MPQ-PRI scores for either group (Table 2).  
 
Between Group Profiles (HF-TENS vs. LF-TENS):  
There was an overall increase in all measures in both groups as shown by the positive change 
values in Figures 2 and 3. The only difference between the groups was in change and 
percentage change in ICD (Mdn (IQR) = 26 (71) with HF-TENS and 6 (67) with LF-TENS, U = 268, z 
= 2.073, p = 0.038, r = 0.49 and Mdn (IQR) = 43 (64) with HF-TENS and 9 (79) with LF-TENS, U = 
267, z = 2.088, p = 0.037, r = 0.49 respectively) (Figures 2 and 3).  
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Discussion:  
The results of this study indicate that compared to placebo, the application of TENS whilst 
walking on a treadmill is associated with a modest but statistically significant improvement of 
walking performance in patients with IC. These results indicate that TENS offers potential as a 
clinically useful intervention that allows patients with IC to walk further before onset of pain, 
and while experiencing pain.   
 
The two different stimulus patterns of TENS employed in this study were found to affect 
distinctive aspects of the pain experience. ICD and ACD increased with HF-TENS whereas only 
ACD increased with LF-TENS. The different stimulus patterns of HF-TENS and LF-TENS appear to 
have activated different mechanisms of hypoalgesia and distinct neurophysiological effects.  
 
Increases in ICD and ACD were observed in the HF-TENS group suggesting an immediate and 
prolonged hypoalgesic effect. Median FCD decreased with HF-TENS intervention however, this 
appeared to be due to the large variance within the sample, as illustrated by an increase in IQR 
(Table 2). Also, when correcting for baseline ability (change scores, Figure 2), median FCD was 
found to be greater than zero therefore indicating an overall increase in walking distance. The 
increases in median ICD and ACD with HF-TENS were found to be significant with effect sizes of 
.69 (p = .004) and .53 (p = .025) respectively (Table 2 and Figures 2 and 3). In the LF-TENS group, 
there was a decrease in median ICD but increases in FCD and ACD suggesting a delayed but 
effective hypoalgesic effect at pain tolerance. The increase in ACD with LF-TENS was found to 
be significant with an effect size of .48 (p = .043) (Table 2). These findings suggest that HF-TENS 
had an immediate and lasting effect; increasing walking distance at the mild (ICD) and more 
severe phases of the pain experience (ACD). The effects of LF-TENS however, were only evident 
when the pain was severe (ACD) indicating a delayed action. These results must be interpreted 
with caution as the significantly lower ABI in the LF-TENS group indicates more severe PAD 
which could have contributed to the poor response. A further variable is the sequencing of the 
placebo after the TENS treatment which could have un-blinded the study for the participants 
and led to less of a response when no stimulation was perceived.  
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HF-TENS is proposed to act by activating large diameter mechanoreceptors (Aβ-fibres), delta 
(δ)-opioid receptors and increasing gamma-Aminobutyric acid (GABA) in the spinal cord. It is 
associated with immediate, localised, segmental inhibition as conceived by the original gate 
control theory.31,32 LF-TENS was originally theorised to act on smaller diameter nociceptive 
afferents, brainstem structures and supraspinal descending pathways, releasing endogenous 
opiates centrally and peripherally.32,33 In contrast to HF-TENS, it was thought that LF-TENS did 
not induce immediate hypoalgesia but had a latent effect of pain relief due to its more complex 
mechanisms.34 These differential mechanisms of action have recently been challenged.35 
Nevertheless, the originally proposed mechanisms of action would explain the characteristics of 
hypoalgesia evident in the current study.  
 
Our ‘proof of concept’ results indicate that HF-TENS improved walking performance during the 
period of treadmill walking that would normally correspond with the first appearance of IC pain 
and when it is growing in intensity. In contrast, LF-TENS did not appear to affect walking 
performance in those portions of the walking exercise. Instead, the effect of LF-TENS 
corresponds with that later period of treadmill walking when IC pain would normally be most 
severe and intolerable.  
 
There is no consensus in the literature regarding modification of which aspect of the IC pain 
experience (ICD, FCD or ACD) results in the greatest gains in walking performance and therefore 
the most effective management. From the results of the current study it would seem that HF-
TENS might be more effective due to the hypoalgesic effects evident throughout the pain 
experience. These conclusions however are tentative and future investigations could further 
explore the relationships between the IC pain experience and different applications of TENS.  
 
Pain relief is thought to be the primary action of TENS however, neither TENS group reported 
any change in MPQ-PRI scores. Whereas the results suggest that pain intensity was not 
affected, an alternative explanation could be related to the experimental methodology. The 
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MPQ was completed at the end of the treadmill test and participants were asked to describe 
their pain at ACD. The participants were therefore walking to the same level of pain intensity on 
both occasions. As discussed above, ACD increased with both types of TENS intervention and 
thus, even though there was no change in maximum pain intensity, the distance walked before 
ACD was reached was greater when using TENS compared to placebo. This result indicates that 
TENS, rather than masking and reducing the experience of maximum pain in patients walking 
with IC pain, prolongs the time taken to reach pain tolerance. This finding is in line with results 
of our experimental study of TENS for laboratory-induced lower limb ischaemic pain in healthy 
volunteers.24,36  
 
Compared to P-TENS, the median change in ACD with HF-TENS was 30 metres (m) and with LF-
TENS, 23m. This relates to percentage increases of 13% for HF-TENS and 18% with LF-TENS 
(Table 3 and Figure 3). A 60% improvement in ACD has been suggested as a functionally 
significant improvement in walking distance for patients with IC.37 The observed effect of TENS 
on walking performance in the current study, conducted within the operational constraints 
imposed by a routine PAD clinic setting, was such that one might anticipate a degree of 
‘dampening’ of the potential effect of TENS. A familiarisation or training effect has been shown 
with the Gardner treadmill test.38 Cognisant of this fact, P-TENS condition was examined on the 
second testing session for every participant. By the nature of this design, any effect of TENS 
observed would be masked by the potential accommodation effect during the second treadmill 
test. The training/accommodation effect for the Gardner treadmill protocol has been found to 
be 15% for ACD.38 With this in mind, the significant increases of 13% and 18% with HF and LF-
TENS may become closer to a clinically worthwhile improvement. IC medication is associated 
with an increase of approximately 30% compared to placebo.39 The change in ACD with TENS 
intervention, taking into account the possible treadmill walking accommodation effect (10%) is 
close to this level of improvement (increase of 23% and 28% compared to placebo). Future 
studies should include treadmill familiarisation and employ a randomised order of entry, 
crossover design to more accurately explore the effect of TENS on walking performance in 
patients with IC.  
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This study makes a novel contribution to the literature on the management of PAD and IC.  
There is no previously published report of the effect of TENS on walking performance and pain 
in this patient population. Our clinical results are also supported by our previous publication on 
HF-TENS for ischaemic pain in healthy volunteers.24 However this is a ‘proof of concept’ study. 
Further study could examine the effectiveness of TENS as an adjunctive intervention for walking 
performance in patients with IC in more detail. For example, further investigation is required 
that examines the effects on pain, haemodynamic changes and gait during treadmill walking. 
There is also a need for investigations that explore the effects of TENS on IC-limited walking in 
people with PAD during more ecologically valid (over ground) walking tasks.  
 
Limitations:  
One aspect of the current study that could be viewed as a limitation is the lack of a no-TENS 
control group. By neglecting to include a no-TENS control condition it was not possible to 
accurately quantify the effect of the placebo effect of TENS. It has been proposed that part of 
the beneficial effect of TENS is the sense of ‘control’ and the perception of receiving an 
‘intervention’ experienced by patients when applying the device. Without a no-TENS group this 
effect cannot be quantified. The study was designed as a proof-of-concept, MRC Phase 2a trial 
and a pragmatic approach was assumed. When investigating the effects of TENS with the aim of 
evaluating physiologically quantifiable outcomes, TENS must demonstrate efficacy above 
placebo therefore the current study design is sufficient. Nevertheless, future studies should 
include a no-TENS control to allow investigation of the placebo response to TENS in PAD and IC.  
 
Another possible limitation of this study was the ordering of intervention. As the treadmill test 
with active TENS preceded the application of placebo for all participants, any effect of TENS 
observed could be temporal. This design was selected to account for participant familiarisation 
with the treadmill test. Previous research has indicated that participants commonly walk 
approximately 15% further during subsequent graded treadmill tests37. What this design 
achieves is that any signal detected (i.e. an increase in walking distance with TENS) must have 
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first exceeded the ‘noise’ of familiarisation. Overall, this design ‘handicapped’ the study and 
ensured that any findings are more cautious.  
 
Conclusions:  
Patients with IC experience a gradual build-up of pain to tolerance when exercising until the 
pain becomes intolerable. The current study aimed to investigate the effects of two types of 
TENS (high and low frequency) on the pain experienced and walking performance in patients 
with PAD and IC. The results indicate that TENS increases the distance walked before tolerance. 
Both types of TENS were found to increase walking performance but HF-TENS was more 
effective at prolonging the time to reach pain threshold.  
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Table 1: Demographic and baseline data for all participants. p values relate to independent 
student’s t-tests (two tailed) of the group values 
 
Table 2: Median (IQR) ICD, FCD and ACD (in metres) and MPQ-PRI scores for both groups with 
placebo and with TENS intervention  
 
Figure 1: CONSORT diagram displaying the progression of participants through the study. 
 
Figure 2: Boxplots representing change in walking measures (metres) with TENS intervention in 
both groups. Positive values represent a positive change with TENS intervention over placebo.   
 
Figure 3: Boxplots representing percentage change in walking measures with TENS intervention 
in both groups. Positive values represent a positive change with TENS intervention over 
placebo.   
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8th January 2015 
Dear Editor,  
 
You had requested clarification regarding a number of points. Please find below an 
explanation of how these issues have been addressed in the revised manuscript.  
1. P2, L55: the sentence beginning with "packaged in a compact ... " is incomplete 
 Manuscript edited to include: “Packaged in a compact, portable unit that is easy to 
apply via small electrodes placed on the skin, a TENS unit can be kept unobtrusively in a 
pocket, or clipped to a trouser belt whilst being used to reduce pain and improve daily 
functioning.” 
2. P4: Was a power calculation completed to determine sample size?  
 As the study was designed as a ‘proof of concept’ trial, a sample size of 40 participants 
was selected as feasible prior to a power calculation. A post-hoc power calculation was 
performed and found that using 80% power and a two-tailed 5% significance level this 
sample would be able to detect a large effect (≥ 0.8; (Cohen 1988)) between two 
groups.  
3. How was group assignment determined?  
 Participants were ‘block randomised’ into the two groups, detailed in the manuscript on 
Page 4, Line 12-14  
4. It's unclear where the placebo walk came in. Why was the TENS walk completed first 
and then the placebo walk. Wouldn't it have been cleaner to randomize the order?  
 The ordering of interventions was an aspect that stimulated much discussion within the 
team. The consensus form previous experience, in addition to review of the literature, 
was that participants often demonstrated a treadmill familiarisation effect i.e. walked 
further during subsequent treadmill tests to a degree of approximately 10-15% (Labs et 
al 1999, Vascular Medicine, 4; pp 239-246). With this in mind, it was decided that the 
most conservative approach should be taken with participants experiencing the active 
TENS condition first.  
 What this design achieves is that any signal detected (i.e. an increase in walking 
distance with TENS) must have first exceeded the noise of familiarisation. Overall, this 
design ‘handicapped’ the study and made sure that any conclusions arrived at were 
more cautious. In addition, participants undertook treadmill familiarisation in 
accordance with the Gardner treadmill protocol (Gardner et al 1991, Medicine and 
Response to Reviewers-this must be 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 Science in Sports and Exercise, 23 pp 402-408). These sessions of treadmill walking 
would have helped to reduce any training effect.   
 Nevertheless, we appreciate the point raised and the ‘Limitations’ includes this 
discussion point and the Discussion reflects that the application of TENS is merely 
“associated” with modest increase in walking performance rather than “elicits”.  
5. Even though the treadmill tester was blinded, didn't they know that the first test was 
the TENS test and the second test placebo?  
 No, the treadmill tester was not aware of the study protocol or the order in which the 
interventions were applied.  
 Manuscript edited to include: “To enhance blinding and reduce the risk of bias, one 
researcher applied the TENS and a different researcher, who was blinded to the study 
protocol and the order of intervention, conducted the treadmill test and recorded the 
primary outcome measures. ”  
6. P5, L47-55: Were patients able to discern the differences between "strong but 
comfortable" and "strong but comfortable and slight muscle twitch"?  
 Participants were aided in this by the researcher who applied all dosing of TENS. For the 
greater intensity required with LF-TENS the researcher ensure slight but visible muscle 
twitch before beginning the treadmill protocol.  
7. p6: please provide a reference for the adjustment for the P-TENS walk (L59) 
 Manuscript edited to include reference to Vickers and Altman 2001, BMJ, 323: 7321, pp 
1123-1124 (Page 6, Line 59)  
8. P8: please list in the narrative, how many patients were assigned to each group 
 Manuscript edited to include: “The remaining 36 participants (18 in each group) were 
included in the analysis”  
 This information is also present in Figure 1 and Table 2.  
9. P8: please provide the ABIs in the HF and LF groups in the narrative 
 Manuscript edited to include: “The LF-TENS group had a significantly lower mean ABI 
(0.57 vs 0.63, t(34) = 2.442)”  
10. P8, L22-31: please provide some numbers in the narrative; I understand the desire not 
to repeat what's in the table but some measure difference would be helpful in the 
narrative 
 Manuscript edited to include: “ICD, FCD and ACD results are detailed in Table 2. 
Compared to placebo TENS, median walking distance increased with TENS intervention 
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 in both groups. This was true with the exception of FCD in the HF-TENS group (Mdn 187 
to 175m) and ICD in the LF-TENS group (Mdn 81 to 76m). All walking-related outcome 
measures changed with HF-TENS intervention. Only ACD changed with LF-TENS 
intervention (Mdn 179 to 288m, Ws = 39, z = 2.025, p = 0.043, r = 0.48). There was no 
change in MPQ-PRI scores for either group (Table 2).”  
11. P9: L50-53: did the authors attempt to adjust the analysis for differences in ABI? 
 Due to the ‘proof of concept’ nature of the study and the limited sample size and 
statistical power this was thought to be beyond the scope of the current study.  
12. p11: The discussion of TM familiarization is a good one. Wouldn't the more logical 
design have bee to allow the patient a practice test and then randomize the order? 
 Most definitely. For future studies and when more resources are available this will be 
the design of choice.  
 Manuscript edited to include: “Future studies should include treadmill familiarisation 
and employ a randomised order of entry, crossover design to more accurately explore 
the effect of TENS on walking performance in patients with IC.” (Page 11)  
13. Table 2: please indicate the units of measure and the final n for each group 
 Table 2 edited as suggested.  
We look forward to your considered response.  
 
Most Sincerely,  
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What is new?  
 TENS may be a useful, cheap, safe and non-invasive adjunct intervention that facilitate 
walking and physical activity in patients with PAD and IC  
 Two different modes of TENS were applied over the site of IC pain during a standardised 
graded treadmill test  
 ICD and ACD increased with High Frequency-TENS but only ACD increased with Low 
Frequency-TENS, compared to Placebo TENS  
 TENS intervention is associated with an increase in treadmill walking performance in 
patients with PAD and IC  
 
What is New (bulleted list of 2-3 highlights from article)
 1 
 
Abstract 
The purpose of this study was to investigate the effects of two types of Transcutaneous 
Electrical Nerve Stimulation (TENS) on walking distance and measures of pain in patients with 
Peripheral Arterial Disease (PAD) and Intermittent Claudication (IC). In a phase 2a study, forty 
participants with PAD and IC completed a graded treadmill test on two separate testing 
occasions. Active TENS was applied to the lower limb on the first occasion and placebo TENS on 
the second. Participants were divided into two experimental groups. One group received High-
Frequency TENS (HF-TENS), the other Low-Frequency TENS (LF-TENS). Measures taken were: 
Initial Claudication Distance (ICD), Functional Claudication Distance (FCD) and Absolute 
Claudication Distance (ACD). The McGill Pain Questionnaire (MPQ) vocabulary was completed 
at the end of the intervention and the MPQ-Pain Rating Index (PRI) score calculated. Four 
participants were excluded from the final analysis due to non-completion of the experimental 
procedure. Median walking distance increased with HF-TENS for all measures (p < .05, Wilcoxon 
signed ranks test, all measures). Only ACD increased significantly with LF-TENS compared to 
placebo (Mdn = 179 to 228, Ws = 39, z = 2.025, p = 0.043, r = 0.48). No difference was observed 
between reported median MPQ-PRI scores: 21.5 with placebo TENS and 21.5 with active TENS 
(p = .41). TENS applied to the lower limb of patients with PAD and IC was associated with 
increased walking distance on a treadmill but not with any reduction in pain. TENS may be a 
useful adjunctive intervention to help increase walking performance in patients with IC.  
 
Keywords  
Peripheral arterial disease, intermittent claudication, transcutaneous electrical nerve 
stimulation (TENS), ischaemic pain, exercise therapy 
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TEXT 
Introduction:  
Peripheral Arterial Disease (PAD) is a clinical manifestation of atherosclerosis. Intermittent 
claudication (IC) is the most common manifestation, and is reported to affect between 10 and 
30% of the population aged above 60 years of age.1 PAD can be asymptomatic in the early 
stages, however as the disease progresses, the increasing atherosclerosis manifests as IC,2 
which is the cardinal symptom of PAD. IC is defined as pain in the lower limb(s) that is 
experienced during walking, and is relieved by rest.3,4 Patients experiencing IC are characterised 
by reduced levels of daily physical activity, which is associated with diminished performance of 
personal, social and occupational activities of daily life. Many individuals become housebound 
or dependent on others5,6 and studies suggest that patients with severe IC have a quality of life 
that equates to those with terminal cancer.7  
 
The management of PAD and IC is primarily through the modification of risk factors, with 
endovascular intervention in severe cases and most medical therapies having only a modest 
benefit. 8,9 Exercise therapy, particularly supervised, is a mainstay of PAD and IC management 
that has been shown to have a significant effect on increasing walking distance, self-reported 
physical activity, measured cardio-respiratory fitness, exercise time and functional ability.3,10-16 
Despite the clear benefits of exercise therapy, over 45% of patients are non-compliant with 
healthcare professional advice to take regular exercise and to walk ‘through’ IC pain.11 The pain 
associated with IC has been identified as a key barrier to walking.17 Although acknowledged as a 
problem, there is little published literature examining analgesic interventions for IC pain.  
 
Transcutaneous Electrical Nerve Stimulation (TENS) is a safe, inexpensive and non-invasive 
method of providing mild electrical stimulation for the relief of pain.18,19 TENS has been 
reported to provide greater analgesic effects than placebo TENS for musculoskeletal,20 
postoperative21 and neuropathic pain.22 Packaged in a compact, portable unit that is easy to 
apply via small electrodes placed on the skin, a TENS unit can be kept unobtrusively in a pocket, 
or clipped to a trouser belt whilst being used to reduce pain and improve daily functioning.23 
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However, thus far TENS has not been tested as a method of reducing pain and improving 
walking related function in patients with IC pain.  
 
There are two main stimulation patterns, or dosages, of TENS employed in clinical practice: 
High-Frequency TENS (HF-TENS) and Low Frequency TENS (LF-TENS). Studies conducted to date 
suggest that the fast-acting, reflexive mechanism of HF-TENS may act most effectively at the 
mild (pain threshold) level of the pain experience. LF-TENS however may act most effectively at 
the stronger (pain tolerance) level of the pain experience due to extrasegmental but longer-
lasting analgesic effects.23  
 
In addition, although TENS has not been widely tested as a method of pain relief of IC, a 
previous investigation observed reductions in pain (hypoalgesia) with High Frequency TENS (HF-
TENS) in healthy volunteers experiencing experimentally-induced ischaemic pain in the lower 
limb.24 This may be due to the focus on exercise, and endovascular intervention as treatments 
for the condition and limited investigation into the nature of IC pain. Also the potential for high 
frequency verses low frequency patterns of TENS to affect different portions of the IC pain 
experience has not been examined.  
 
We hypothesised that the two types of TENS might favourably, but differentially, affect discrete 
portions of the IC pain experience; for instance, when pain is mild (which normally occurs in 
PAD patients after walking a short distance), or when it becomes more severe (during 
continued walking). We therefore aimed to investigate the effects of HF and LF-TENS on 
measures of pain and walking performance in patients with PAD and IC.  
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Material and Methods:  
Participants:  
Ethical approval for the study was obtained from the NHS East of Scotland Research Ethics 
Service (Reference Number: 09/S1402/15). Forty participants with stable PAD and IC were 
recruited from the vascular outpatient clinic at Ninewells Hospital, Dundee, Scotland and block 
randomised into two experimental groups (HF-TENS and LF-TENS). Participants provided 
written informed consent and were included if they had: clinical diagnosis of PAD and stable IC 
of more than 3 months duration; Fontaine stage II claudication; resting Ankle Brachial Index 
(ABI) less than 0.90 in at least one leg; walking limited only by claudication; independent and 
safe mobility (no walking aids); were cognitively stable and able to follow instruction and were 
able to read and complete the questionnaires. Participants were excluded if they were: less 
than 40 years of age; had planned surgical or endovascular intervention for PAD; co-morbidities 
causing pain in the lower limb; ataxic gait or history of increased falls (unsafe for treadmill 
walking); myocardial infarction within the previous 6 months, cardiac arrhythmia or a cardiac 
pacemaker; current or previous sensation abnormalities in the lower limbs; epilepsy; medical 
diagnosis or self-reported psychiatric illness or previous experience of using TENS.  
 
Study Protocol:  
The experimental study design was a single blind, placebo-controlled, phase 2a, proof-of-
concept trial. Each participant attended for two sessions, six to nine days apart with the 
majority of participants (n=30) completing both tests within seven days. A graded treadmill 
protocol25 was completed by the participant at each. On the first occasion active TENS was 
applied and placebo TENS (P-TENS) on the second. For the purpose of blinding, the participants 
were told that “different ‘dosages’ of TENS were being tested, some of which may not be 
perceptible”. To enhance blinding and reduce the risk of bias, one researcher applied the TENS 
and a different researcher, who was blinded to the study protocol and the order of 
intervention, conducted the treadmill test and recorded the primary outcome measures.  
 
Treadmill Procedure: 
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The treadmill procedure followed that described by Gardner et al 25 using a GE Marquette 
treadmill. Participants were connected to a 12-lead Echocardiograph (12-lead ECG) (GE CASE 
Premium Stress System), which recorded continuously throughout the procedure. A 
familiarisation session was completed first where participants practiced walking at different 
speeds (1, 1.5 and 2mph) and the self-report method of rating claudication symptoms was 
explained. Further safety instructions were also issued: the participants were reminded to 
report any feelings of pain distinct from claudication and any feelings of dizziness/light-
headedness immediately so that the test could be stopped. This series of events took less than 
10 minutes to complete and the participant walked for a maximum of 30 seconds at each 
treadmill speed. Once this familiarisation procedure was completed, participants rested supine 
on a bed for 15 minutes in preparation for the full treadmill test.  
 
TENS Procedure:  
A NeuroTrac 3™ TENS machine (Verity Medical Ltd, Surrey, UK) was fitted to the participant five 
minutes prior to each treadmill test and continued throughout the procedure. A segmental 
electrode application was employed using self-adhesive carbon rubber electrodes measuring 
5x5 cm (PhysioMed PALS® electrodes, Glossop, UK). The two electrodes were attached to the 
TENS unit via the manufacturer leads. The area of pain reported by the participant during the 
familiarisation session determined the electrode placement sites. The placement sites were at 
least 2cm apart. Electrodes were commonly placed with one proximal and one distal to the 
gastrocnemius muscle belly.  
 
The TENS machine was calibrated prior to use with a digital oscilloscope and tested manually by 
the investigator prior to every testing session. The HF-TENS stimulation parameters were 
calibrated to 120Hz, pulse width 200μs and patient determined intensity of “strong but 
comfortable”. The LF-TENS stimulation was set at 2Hz, pulse width 200μs and patient 
determined intensity of “strong but comfortable and slight muscle twitch”.  
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The placebo TENS (P-TENS) condition used the same TENS model and programmed settings but 
with an inconspicuous break in the wires. This allowed the unit to be switched on with the 
appearance of a working unit but without any current reaching the participant. This was 
checked and confirmed with the use of an oscilloscope as described above.  
 
Measures:  
Participants were instructed to report:  
1. When they first experienced claudication symptoms (Initial Claudication Distance (ICD)) 
25 
2. When they reached the point at which they would usually stop walking (Functional 
Claudication Distance (FCD)) 26,27 
3. When they could not walk any further due to claudication symptoms (Absolute 
Claudication Distance (ACD)) 25  
 
Pain quality and intensity was recorded using a McGill Pain Questionnaire (MPQ); 28 
administered 5 minutes after the participant completed the treadmill protocol. The MPQ 
consists of a vocabulary of adjectives from which the participant chooses appropriate words to 
describe the particular qualities of IC pain and accompanying feelings of distress and 
intrusion.29  
 
Statistical Analysis:  
The mean scores for ICD, FCD and ACD were positively skewed and showed heteroscedascity. A 
log (10) transformation applied to normalise the data did not address the variance within the 
data, thus non-parametric statistics were used to analyse the data.  
 
Wilcoxon Signed Ranks tests examined within-group differences in treadmill measures and 
MPQ-PRI scores. In order to reduce the effect of inter-participant variability, individual change 
in ICD, FCD and ACD between P-TENS and Active TENS was calculated for each participant. 
Distance walked with P-TENS was subtracted from the distance walked with Active TENS. 30 
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Individual percentage change was also calculated for ICD, FCD and ACD. The difference between 
the two sessions was calculated as a percentage of the distance walked with P-TENS. These 
values were then analysed using Mann-Whitney U tests for between-group comparisons. 
Statistical significance was set at p = 0.05 (two-tailed) and analysis was performed using SPSS 
version 19.0.  
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Results:  
Participants:  
Four participants were excluded from analysis due to non-completion of the experimental 
procedure. Three had previously unknown exercise-limiting co-morbidities and one was unable 
to walk safely on the treadmill. The remaining 36 participants (18 in each group) were included 
in the analysis (29 male, mean age (range) = 70 (54-87) years). Figure 1 summarises this 
information and displays the flow of participants through the study. The groups were similar in 
terms of demographic and disease data. The LF-TENS group had a significantly lower mean ABI 
(0.57 vs 0.63, t(34) = 2.442) (Table 1). 
 
Within Group Profiles (HF-TENS and LF-TENS vs. P-TENS):  
ICD, FCD and ACD results are detailed in Table 2. Compared to placebo TENS, median walking 
distance increased with TENS intervention in both groups. This was true with the exception of 
FCD in the HF-TENS group (Mdn 187 to 175m) and ICD in the LF-TENS group (Mdn 81 to 76m). 
All walking-related outcome measures changed with HF-TENS intervention. Only ACD changed 
with LF-TENS intervention (Mdn 179 to 288m, Ws = 39, z = 2.025, p = 0.043, r = 0.48). There was 
no change in MPQ-PRI scores for either group (Table 2).  
 
Between Group Profiles (HF-TENS vs. LF-TENS):  
There was an overall increase in all measures in both groups as shown by the positive change 
values in Figures 2 and 3. The only difference between the groups was in change and 
percentage change in ICD (Mdn (IQR) = 26 (71) with HF-TENS and 6 (67) with LF-TENS, U = 268, z 
= 2.073, p = 0.038, r = 0.49 and Mdn (IQR) = 43 (64) with HF-TENS and 9 (79) with LF-TENS, U = 
267, z = 2.088, p = 0.037, r = 0.49 respectively) (Figures 2 and 3).  
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Discussion:  
The results of this study indicate that compared to placebo, the application of TENS whilst 
walking on a treadmill is associated with a modest but statistically significant improvement of 
walking performance in patients with IC. These results indicate that TENS offers potential as a 
clinically useful intervention that allows patients with IC to walk further before onset of pain, 
and while experiencing pain.   
 
The two different stimulus patterns of TENS employed in this study were found to affect 
distinctive aspects of the pain experience. ICD and ACD increased with HF-TENS whereas only 
ACD increased with LF-TENS. The different stimulus patterns of HF-TENS and LF-TENS appear to 
have activated different mechanisms of hypoalgesia and distinct neurophysiological effects.  
 
Increases in ICD and ACD were observed in the HF-TENS group suggesting an immediate and 
prolonged hypoalgesic effect. Median FCD decreased with HF-TENS intervention however, this 
appeared to be due to the large variance within the sample, as illustrated by an increase in IQR 
(Table 2). Also, when correcting for baseline ability (change scores, Figure 2), median FCD was 
found to be greater than zero therefore indicating an overall increase in walking distance. The 
increases in median ICD and ACD with HF-TENS were found to be significant with effect sizes of 
.69 (p = .004) and .53 (p = .025) respectively (Table 2 and Figures 2 and 3). In the LF-TENS group, 
there was a decrease in median ICD but increases in FCD and ACD suggesting a delayed but 
effective hypoalgesic effect at pain tolerance. The increase in ACD with LF-TENS was found to 
be significant with an effect size of .48 (p = .043) (Table 2). These findings suggest that HF-TENS 
had an immediate and lasting effect; increasing walking distance at the mild (ICD) and more 
severe phases of the pain experience (ACD). The effects of LF-TENS however, were only evident 
when the pain was severe (ACD) indicating a delayed action. These results must be interpreted 
with caution as the significantly lower ABI in the LF-TENS group indicates more severe PAD 
which could have contributed to the poor response. A further variable is the sequencing of the 
placebo after the TENS treatment which could have un-blinded the study for the participants 
and led to less of a response when no stimulation was perceived.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 10 
 
 
HF-TENS is proposed to act by activating large diameter mechanoreceptors (Aβ-fibres), delta 
(δ)-opioid receptors and increasing gamma-Aminobutyric acid (GABA) in the spinal cord. It is 
associated with immediate, localised, segmental inhibition as conceived by the original gate 
control theory.31,32 LF-TENS was originally theorised to act on smaller diameter nociceptive 
afferents, brainstem structures and supraspinal descending pathways, releasing endogenous 
opiates centrally and peripherally.32,33 In contrast to HF-TENS, it was thought that LF-TENS did 
not induce immediate hypoalgesia but had a latent effect of pain relief due to its more complex 
mechanisms.34 These differential mechanisms of action have recently been challenged.35 
Nevertheless, the originally proposed mechanisms of action would explain the characteristics of 
hypoalgesia evident in the current study.  
 
Our ‘proof of concept’ results indicate that HF-TENS improved walking performance during the 
period of treadmill walking that would normally correspond with the first appearance of IC pain 
and when it is growing in intensity. In contrast, LF-TENS did not appear to affect walking 
performance in those portions of the walking exercise. Instead, the effect of LF-TENS 
corresponds with that later period of treadmill walking when IC pain would normally be most 
severe and intolerable.  
 
There is no consensus in the literature regarding modification of which aspect of the IC pain 
experience (ICD, FCD or ACD) results in the greatest gains in walking performance and therefore 
the most effective management. From the results of the current study it would seem that HF-
TENS might be more effective due to the hypoalgesic effects evident throughout the pain 
experience. These conclusions however are tentative and future investigations could further 
explore the relationships between the IC pain experience and different applications of TENS.  
 
Pain relief is thought to be the primary action of TENS however, neither TENS group reported 
any change in MPQ-PRI scores. Whereas the results suggest that pain intensity was not 
affected, an alternative explanation could be related to the experimental methodology. The 
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MPQ was completed at the end of the treadmill test and participants were asked to describe 
their pain at ACD. The participants were therefore walking to the same level of pain intensity on 
both occasions. As discussed above, ACD increased with both types of TENS intervention and 
thus, even though there was no change in maximum pain intensity, the distance walked before 
ACD was reached was greater when using TENS compared to placebo. This result indicates that 
TENS, rather than masking and reducing the experience of maximum pain in patients walking 
with IC pain, prolongs the time taken to reach pain tolerance. This finding is in line with results 
of our experimental study of TENS for laboratory-induced lower limb ischaemic pain in healthy 
volunteers.24,36  
 
Compared to P-TENS, the median change in ACD with HF-TENS was 30 metres (m) and with LF-
TENS, 23m. This relates to percentage increases of 13% for HF-TENS and 18% with LF-TENS 
(Table 3 and Figure 3). A 60% improvement in ACD has been suggested as a functionally 
significant improvement in walking distance for patients with IC.37 The observed effect of TENS 
on walking performance in the current study, conducted within the operational constraints 
imposed by a routine PAD clinic setting, was such that one might anticipate a degree of 
‘dampening’ of the potential effect of TENS. A familiarisation or training effect has been shown 
with the Gardner treadmill test.38 Cognisant of this fact, P-TENS condition was examined on the 
second testing session for every participant. By the nature of this design, any effect of TENS 
observed would be masked by the potential accommodation effect during the second treadmill 
test. The training/accommodation effect for the Gardner treadmill protocol has been found to 
be 15% for ACD.38 With this in mind, the significant increases of 13% and 18% with HF and LF-
TENS may become closer to a clinically worthwhile improvement. IC medication is associated 
with an increase of approximately 30% compared to placebo.39 The change in ACD with TENS 
intervention, taking into account the possible treadmill walking accommodation effect (10%) is 
close to this level of improvement (increase of 23% and 28% compared to placebo). Future 
studies should include treadmill familiarisation and employ a randomised order of entry, 
crossover design to more accurately explore the effect of TENS on walking performance in 
patients with IC.  
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This study makes a novel contribution to the literature on the management of PAD and IC.  
There is no previously published report of the effect of TENS on walking performance and pain 
in this patient population. Our clinical results are also supported by our previous publication on 
HF-TENS for ischaemic pain in healthy volunteers.24 However this is a ‘proof of concept’ study. 
Further study could examine the effectiveness of TENS as an adjunctive intervention for walking 
performance in patients with IC in more detail. For example, further investigation is required 
that examines the effects on pain, haemodynamic changes and gait during treadmill walking. 
There is also a need for investigations that explore the effects of TENS on IC-limited walking in 
people with PAD during more ecologically valid (over ground) walking tasks.  
 
Limitations:  
One aspect of the current study that could be viewed as a limitation is the lack of a no-TENS 
control group. By neglecting to include a no-TENS control condition it was not possible to 
accurately quantify the effect of the placebo effect of TENS. It has been proposed that part of 
the beneficial effect of TENS is the sense of ‘control’ and the perception of receiving an 
‘intervention’ experienced by patients when applying the device. Without a no-TENS group this 
effect cannot be quantified. The study was designed as a proof-of-concept, MRC Phase 2a trial 
and a pragmatic approach was assumed. When investigating the effects of TENS with the aim of 
evaluating physiologically quantifiable outcomes, TENS must demonstrate efficacy above 
placebo therefore the current study design is sufficient. Nevertheless, future studies should 
include a no-TENS control to allow investigation of the placebo response to TENS in PAD and IC.  
 
Another possible limitation of this study was the ordering of intervention. As the treadmill test 
with active TENS preceded the application of placebo for all participants, any effect of TENS 
observed could be temporal. This design was selected to account for participant familiarisation 
with the treadmill test. Previous research has indicated that participants commonly walk 
approximately 15% further during subsequent graded treadmill tests37. What this design 
achieves is that any signal detected (i.e. an increase in walking distance with TENS) must have 
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first exceeded the ‘noise’ of familiarisation. Overall, this design ‘handicapped’ the study and 
ensured that any findings are more cautious.  
 
Conclusions:  
Patients with IC experience a gradual build-up of pain to tolerance when exercising until the 
pain becomes intolerable. The current study aimed to investigate the effects of two types of 
TENS (high and low frequency) on the pain experienced and walking performance in patients 
with PAD and IC. The results indicate that TENS increases the distance walked before tolerance. 
Both types of TENS were found to increase walking performance but HF-TENS was more 
effective at prolonging the time to reach pain threshold.  
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Table 1: Demographic and baseline data for all participants. p values relate to independent 
student’s t-tests (two tailed) of the group values 
 
Table 2: Median (IQR) ICD, FCD and ACD (in metres) and MPQ-PRI scores for both groups with 
placebo and with TENS intervention  
 
Figure 1: CONSORT diagram displaying the progression of participants through the study. 
 
Figure 2: Boxplots representing change in walking measures (metres) with TENS intervention in 
both groups. Positive values represent a positive change with TENS intervention over placebo.   
 
Figure 3: Boxplots representing percentage change in walking measures with TENS intervention 
in both groups. Positive values represent a positive change with TENS intervention over 
placebo.   
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
 
References:   
1. Belch J, Stansby G, Shearman C, et al. Peripheral arterial disease -- a cardiovascular time 
bomb. The British Journal of Diabetes & Vascular Disease. 2007;7(5):236-239.  
2. Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance 
measures for adults with peripheral artery disease: A report of the american college of 
cardiology Foundation/American heart association task force on performance measures, the 
american college of radiology, the society for cardiac angiography and interventions, the society 
for interventional radiology, the society for vascular medicine. Circulation. 2010;122(24):2583-
2618.  
3. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Medical progress: Exercise training for 
claudication. New Engl J Med. 2002;347(24):1941-1951.  
4. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus 
non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 
2006(2).  
5. Falcone RA, Hirsch AT, Regensteiner JG, et al. Peripheral arterial disease rehabilitation: A 
review. J Cardiopulm Rehabil. 2003;23(3):170-175.  
6. Aquarius AE, De Vries J, Van Berge Henegouwen DP, Hamming JF. Clinical indicators and 
psychosocial aspects in peripheral arterial disease. Archives of Surgery. 2006;141(2):161-166.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
 
7. Belch JJF, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and 
management: A call to action. Arch Intern Med. 2003;163(8):884-92.  
8. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society 
consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(1 
SUPPL.):S5-S67.  
9. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of peripheral 
arterial disease: A national clinical guideline. Edinburgh, Scottish Intercollegiate Guidelines 
Network. 2006;89.  
10. Gardner aW, Poehlman ET. Exercise rehabilitation programs for the treatment of 
claudication pain. A meta-analysis. JAMA : the journal of the American Medical Association. 
1995;274(12):975-80.  
11. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst 
Rev. 2000(2).  
12. Gardner AW, Katzel LI, Sorkin JD, et al. Exercise rehabilitation improves functional outcomes 
and peripheral circulation in patients with intermittent claudication: A randomized controlled 
trial. J Am Geriatr Soc. 2001;49(6):755-762.  
13. Bulmer AC, Coombes JS. Optimising exercise training in peripheral arterial disease. Sports 
Med. 2004;34(14):983-1003.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
 
14. McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: 
A slower rate of decline in patients who walk more. Ann Intern Med. 2006;144(1):10-20.  
15. Gardner AWP, Afaq z,M.D. Management of lower extremity peripheral arterial disease. 
[review]. Journal of Cardiopulmonary Rehabilitation & Prevention. 2008;28(6):349-357.  
16. Mcdermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in 
patients with peripheral arterial disease with and without intermittent claudication. . 
2009;301(2):165-174.  
17. Galea MN, Bray SR, Martin Ginis KA. Barriers and facilitators for walking in individuals with 
intermittent claudication. J Aging Phys Act. 2008;16(1):69-84.  
18. Johnson MI. Transcutaneous electrical nerve stimulation (TENS) and TENS-like devices: Do 
they provide pain relief? Pain Rev. 2001;8(3-4):121-158.  
19. Johnson M. Transcutaneous electrical nerve stimulation: Mechanisms, clinical application 
and evidence. Reviews in Pain. 2007;1(1):7-11.  
20. Law PPW, Cheing GLY. Optimal stimulation frequency of transcutaneous electrical nerve 
stimulation on people with knee osteoarthritis. J Rehabil Med. 2004;36(5):220-225.  
21. Hamza MA, White PF, Ahmed HE, Ghoname E-A. Effect of the frequency of transcutaneous 
electrical nerve stimulation on the postoperative opioid analgesic requirement and recovery 
profile. Anesthesiology. 1999;91(5):1232-1238.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
 
22. Somers DL, Somers MF. Treatment of neuropathic pain in a patient with diabetic 
neuropathy using transcutaneous electrical nerve stimulation applied to the skin of the lumbar 
region. Phys Ther. 1999;79(8):767-775.  
23. Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: Basic science mechanisms 
and clinical effectiveness. The Journal of Pain. 2003;4(3):109-121.  
24. Seenan C, Roche PA, Tan C-, Mercer T. Modification of experimental, lower limb ischemic 
pain with transcutaneous electrical nerve stimulation. Clin J Pain. 2012;28(8):693-699.  
25. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests 
for evaluation of claudication. Med Sci Sports Exerc. 1991;23(4):402-408.  
26. Kruidenier LM, Nicolaï SPA, Willigendael EM, de Bie RA, Prins MH, Teijink JAW. Functional 
claudication distance: A reliable and valid measurement to assess functional limitation in 
patients with intermittent claudication. BMC Cardiovasc Disord. 2009;9.  
27. NicolaÃ¯ S,P.a, Leffers P, Kruidenier LM, De Bie Ra, Prins MH, Teijink JaW. Extending the 
range of treadmill testing for patients with intermittent claudication. Med Sci Sports Exerc. 
2010;42(4):640-5.  
28. Melzack R. The McGill pain questionnaire: Major properties and scoring methods. Pain. 
1975;1(3):277-299.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
 
29. Dworkin RH, Turk DC, Revicki DA, et al. Development and initial validation of an expanded 
and revised version of the short-form McGill pain questionnaire (SF-MPQ-2). Pain. 2009;144(1-
2):35-42.  
30. Vickers AJ, Altman DG. BMJ. 2001;323(7321):1123-1124. doi: 10.1136/bmj.323.7321.1123.  
31. Melzack R, Wall PD. Pain mechanisms: A new theory. Science. 1965;150(3699):971-979.  
32. DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA. Effectiveness of transcutaneous 
electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheumatol Rep. 
2008;10(6):492-499.  
33. Sjolund B, Terenius L, Eriksson M. Increased cerebrospinal fluid levels of endorphins after 
electro-acupuncture. Acta Physiol Scand. 1977;100(3):382-384.  
34. Le Bars D. The whole body receptive field of dorsal horn multireceptive neurones. Brain 
research.Brain research reviews. 2002;40(1-3):29-44.  
35. Radhakrishnan R, Sluka KA. Deep tissue afferents, but not cutaneous afferents, mediate 
transcutaneous electrical nerve Stimulation–Induced antihyperalgesia. The Journal of Pain. 
2005;6(10):673-680.  
36. Chen C, Tabasam G, Johnson MI. Does the pulse frequency of transcutaneous electrical 
nerve stimulation (TENS) influence hypoalgesia? Physiotherapy. 2008;94(1):11-20.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
 
37. Oakley C, Zwierska I, Tew G, Beard JD, Saxton JM. Nordic poles immediately improve 
walking distance in patients with intermittent claudication. Eur J Vasc Endovasc Surg. 
2008;36(6):689-694.  
38. Labs K-, Nehler MR, Roessner M, Jaeger KA, Hiatt WR. Reliability of treadmill testing in 
peripheral arterial disease: A comparison of a constant load with a graded load treadmill 
protocol. Vasc Med. 1999;4(4):239-246.  
39. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. 
Drug therapy for improving walking distance in intermittent claudication: A systematic review 
and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 
2009;38(4):463-474.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 
All 
Group  
 HF-TENS LF-TENS  
Characteristic  Mean SD Mean SE Mean SE p value 
Age (years) 70 8.0 68 1.8 71 1.9 0.344 
BMI (kg/m2) 28 4.2 29 1.0 27 1.0 0.261 
HR (bpm) 71 9.4 71 2.0 71 2.4 0.986 
BP (sys) (mmHg) 146 18.1 147 5.2 146 3.2 0.943 
ABI (AU) .63 .164 .70 .041 .57 .031 0.020* 
ICD (m) 86 51.7 85 15.5 88 8.1 0.867 
FCD (m) 202 127.1 222 32.4 182 27.4 0.351 
ACD (m) 259 169.2 268 39.4 250 41.4 0.750 
MPQ-PRI (0-78) 21 7.9 20 1.9 23 1.8 0.219 
BMI = body mass index; HR = heart rate; BP (sys) = systolic blood pressure;  
ABI = ankle brachial index (measured in arbitrary units (AU)); ICD = initial claudication 
distance; FCD = functional claudication distance; ACD = absolute claudication distance; 
MPQ-PRI (0-78) = McGill pain questionnaire pain rating index 
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  Placebo Intervention p Ws r 
HF-TENS Group  
(n = 18) 
ICD (m) 61 (68) 82 (112) .004* 18 .69 
FCD (m) 187 (175) 175 (303) .025* 34 .53 
ACD (m) 211 (244) 212 (297) .025* 34 .53 
MPQ-PRI (au) 19 (8.5) 24 (13.3) .476 48 .17 
LF-TENS Group  
(n = 18) 
ICD (m) 81 (38) 76 (50) .965 85 .01 
FCD (m) 151 (130) 158 (114) .687 62 .16 
ACD (m) 179 (153) 228 (218) .043* 39 .48 
MPQ-PRI (au) 24 (11.5) 21 (17) .601 74 .12 
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